AbstractObjective To evaluate the clinical efficacy and toxicity of intensity-modulated radiation therapy (IMRT) following prostatectomy for elderly patients with prostate cancer. Methods Ninety-eight prostate cancer patients receiving IMRT after prostatectomy were included in this study. The median age was 68 years old. The number of patients with low-,middle-and high-risk prostate cancer was 10,21 and 67,respectively. Two patients had oligometastases (pelvic bone metastases).Sixty-four patients were treated with IMRT combined with endocrine therapy. Among them,43 cases received adjuvant volumetric modulated arc therapy (VMAT),and 55 patients received salvage IMRT.The median radiotherapy dose was 72 Gy for the tumor bed. Twenty-nine patients received radiotherapy of the pelvic node region with a median dose of 50 Gy. Results The median follow-up time was 40 months. The 5-year overall survival (OS),biochemical recurrence-free survival (BRFS) and local control (LC) were 90%,76% and 100%,respectively. The OS (88.8% vs. 90.8%,P=0.94),BRFS (75.9% vs. 71%,P=0.79) or LC (100% vs. 100%,P=0.32) did not significantly differ between the adjuvant and salvage radiotherapy groups,respectively. The incidence of grade I-Ⅱ late rectal toxicities was 24.1%,and no ≥ grade 3 late toxicity was observed. The incidence of grade 1-2 late bladder toxicities was 29.9%,and 3.4% for grade 3. Conclusion IMRT following prostatectomy yields high clinical efficacy and slight late toxicities in elderly patients with prostate cancer.
Corresponding Authors:
Li Gaofeng,Email:lgf6243@163.com
Cite this article:
Xu Yonggang,Zhong Qiuzi,Gao Hong et al. Clinical efficacy and toxicity of intensity-modulated radiation therapy following prostatectomy for 98 elderly patients with prostate cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(5): 349-352.
Xu Yonggang,Zhong Qiuzi,Gao Hong et al. Clinical efficacy and toxicity of intensity-modulated radiation therapy following prostatectomy for 98 elderly patients with prostate cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(5): 349-352.
[1] Bolla M,van Poppel H,Tombal B,et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer:long-term results of a randomised controlled trial (EORTC trial 22911)[J].Lancet,2012,380(11):2018-2027.DOI:10.1016/S0140-6736(12)61253-7. [2] Thompson IM,Tangen CM,Paradelo J,et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival:long-term followup of a randomized clinical trial[J].J Urol,2009,18(5):956-962.DOI:10.1016/j.juro.2008.11.032. [3] Wiegel T,Bottke D,Steiner U,et al. Phase Ⅲ postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen:ARO 96-02/AUO AP 09/95[J].J Clin Oncol,2009,27(18):2924-30.DOI:10.1200/JCO.2008.18.9563. [4] Pisansky TM,Agrawal S,Hamstra DA,et al. Salvage radiation therapy dose response for biochemical failure of prostate cancer after prostatectomy-a multi-institutional observational study[J].Int J Radiat Oncol Biol Phys,2016,96(11):1046-1053.DOI:10.1016/j.ijrobp.2016.08.043. [5] Carrie C,Hasbini A,de Laroche G,et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16):a randomised,multicentre,open-label phase 3 trial[J].Lancet Oncol,2016,17(4):747-756.DOI:10.1016/S1470-2045(16) 00111-X. [6] Fossati N,Karnes RJ,Boorjian SA,et al. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy:results from a multi-institutional series[J].Eur Urol,2017,71(6):886-893.DOI:10.1016/j.eururo.2016.07.028. [7] Briganti A,Wiegel T,Joniau S,et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy:results of a match-controlled multi-institutional analysis[J].Eur Urol,2012,62(3):472-487.DOI:10.1016/j.urolonc.2012.08.005. [8] Parker C,Sydes MR,Catton C,et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS):a new medical research council/National cancer institute of Canada phase Ⅲ trial of adjuvant treatment after radical prostatectomy[J].BJU Int,2007,99(6):1376-1379.DOI:10.1111/j.1464-410X.2007.06844.x [9] Pearse M,Fraser-Browne C,Davis ID,et al. A Phase Ⅲ trial to investigate the timing of radiotherapy for prostate cancer with high-risk features:background and rationale of the radiotherapy-adjuvant versus early salvage (RAVES) trial[J].BJU Int,2014,113(Suppl 2):7-12.DOI:10.1111/bju.12623. [10] Zelefsky MJ,Levin EJ,Hunt M,et al. Incidence of late re ctal and urinary toxicities after three-dimensional conformal r adiotherapy and intensity-modulated radiotherapy for localized prostate cancer[J].Int J Radiat Oncol Biol Phys,2008,70(6):1124-1129.DOI:10.1038/sj.pcan.4500910. [11] Jani AB,Su A,Correa D,Gratzle J.Comparison of late gas trointestinal and genitourinary toxicity of prostate cancer pat ients undergoing intensity-modulated versus conventional radiot herapy using localized fields[J].Prost Cancer Prost Dis,2007,10(1):82-86.DOI:10.1038/sj.pcan.4500910. [12] Xu N,Rossi PJ,Jani AB.Toxicity analysis of dose escalat ion from 75.6 gy to 81.0 gy in prostate cancer[J].Am J Clin Oncol,2011,34(1):11-15.DOI:10.1097/COC.0b013e3181cae8c6. [13] Ehmann M,Wenz F.Early postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer. Long-term results of the EORTC trial 22911[J].Strahlenther Onkol,2013,189(5):431-432.DOI:10.1007/s00066-013-0333-2. [14] Wiegel T,Bartkowiak D,Bottke D,et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy:10-year follow-up of the ARO 96-02/AUO AP 09/95 trial[J].Eur Urol,2014,66(2):243-250.DOI:10.1016/j.eururo.2014.03.011. [15] Valicenti RK,Thompson I Jr,Albertsen P,et al. Adjuvant and salvage radiation therapy after prostatectomy:American society for radiation oncology/American urological association guidelines[J].Int J Radiat Oncol Biol Phys,2013,86(5):822-828.DOI:10.1016/j.ijrobp.2013.05.029.
2019, Vol. 28 
